Division of Johnson & Johnson
Latest From Janssen-Cilag GmbH
Half of the newly selected imported drugs slated for fast track review in China are rare disease treatments, followed by antiviral drugs for influenza and HIV, reflecting key medical needs in the country.
Appointments: Eli Lilly, Alexion, Actelion, Polyphor, Constellation, Bone Therapeutics and Allied Minds
This week's roundup includes the announced retirement of Lilly's CFO, high-level appointments by Alexion Pharmaceuticals, Actelion and Constellation, and board elections by Wilson Therapeutics, Bone Therapeutics and Atlantic Healthcare.
2016 saw 30 new active substances approved in the EU, in a total of 29 different products, of which 10 were for cancer indications. Also approved were a range of combinations of old and new drugs, some new uses, and a number of biosimilars and generics. 14 of the products approved during the year were for rare diseases, while eight received a conditional marketing authorization.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Johnson & Johnson
- Senior Management
- Contact Info
Phone: 02 137 9550
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.